BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/20/2025 8:05:12 AM | Browse: 131 | Download: 1112
 |
Received |
|
2025-03-09 09:28 |
|
Peer-Review Started |
|
2025-03-09 09:28 |
|
First Decision by Editorial Office Director |
|
2025-03-25 08:07 |
|
Return for Revision |
|
2025-03-25 08:07 |
|
Revised |
|
2025-04-07 16:30 |
|
Publication Fee Transferred |
|
2025-04-09 12:19 |
|
Second Decision by Editor |
|
2025-04-29 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-04-29 07:47 |
|
Articles in Press |
|
2025-04-29 07:47 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-06-09 03:21 |
|
Publish the Manuscript Online |
|
2025-06-20 08:05 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shuai Liu, Yao-Hui Liu, Hong-Bo Ni, Jia-Jian Li, Ze-Tao Wu, Luo-Luo Wang, Yi Ruan and Xin-Hua Zhou |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Zhejiang Province Medicine and Health Science and Technology Project |
No. 2023KY239 |
| Zhejiang Province Traditional Chinese Medicine Science and Technology Plan Project |
No. 2024ZL949 |
|
| Corresponding Author |
Xin-Hua Zhou, Chief Physician, Professor, Department of Hepatobiliary and Pancreatic Surgery, Li Huili Hospital Affiliated to Ningbo University, No. 1111 Jiangnan Road, Yinzhou District, Ningbo 315000, Zhejiang Province, China. zhouxinhua1002@163.com |
| Key Words |
Transarterial chemoembolization; Hepatocellular carcinoma; Portal vein tumor thrombus; Programmed cell death protein-1; Propensity score matching; Lenvatinib |
| Core Tip |
This study evaluates the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib plus death protein-1 inhibitors (TACE-L-P) vs TACE combined with lenvatinib (TACE-L) in treating hepatocellular carcinoma with portal vein tumor thrombus (HCC-PVTT). The TACE-L-P regimen showed significantly improved overall survival, progression-free survival, and response rates compared to TACE-L. The safety profiles were comparable, with no severe treatment-related adverse events. These findings suggest that TACE-L-P may be a promising therapeutic option for HCC-PVTT patients. |
| Publish Date |
2025-06-20 08:05 |
| Citation |
Liu S, Liu YH, Ni HB, Li JJ, Wu ZT, Wang LL, Ruan Y, Zhou XH. Transarterial chemoembolization plus lenvatinib with or without protein-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus. World J Clin Oncol 2025; 16(6): 106798
|
| URL |
https://www.wjgnet.com/2218-4333/full/v16/i6/106798.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v16.i6.106798 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
